BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received an average rating of “Moderate Buy” from 14 brokerages, with 11 analysts recommending a buy and three a hold.
• The current average target price for BioNTech shares is $134.56, with Goldman Sachs setting a neutral rating at a target price of $110.00.
• In its recent earnings report, BioNTech missed EPS estimates but reported a revenue of $306.46 million, which is a 102.6% increase compared to the same quarter last year.

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been given an average rating of "Moderate Buy" by the fourteen brokerages that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $134.5627.

Several analysts recently issued reports on BNTX shares. The Goldman Sachs Group started coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a "neutral" rating and a $110.00 target price for the company. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Leerink Partners set a $112.00 target price on shares of BioNTech in a research report on Monday, June 2nd. Morgan Stanley boosted their target price on shares of BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 10th. Finally, Bank of America upped their price target on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $98.72 on Tuesday. The firm has a 50 day moving average of $107.10 and a 200 day moving average of $103.31. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $23.73 billion, a price-to-earnings ratio of -61.70 and a beta of 1.39. BioNTech has a 12-month low of $81.20 and a 12-month high of $129.27.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business's quarterly revenue was up 102.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, research analysts anticipate that BioNTech will post -3.88 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently modified their holdings of BNTX. Banque Cantonale Vaudoise bought a new position in shares of BioNTech in the first quarter worth approximately $36,000. LRI Investments LLC boosted its position in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company's stock worth $47,000 after purchasing an additional 312 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock worth $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. boosted its position in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock worth $61,000 after purchasing an additional 472 shares during the period. Finally, Banque Transatlantique SA bought a new position in shares of BioNTech in the first quarter worth approximately $80,000. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.